Novo's weekly insulin secures CHMP thumbs-up as FDA decision looms

22 Mar 2024

Drug Approval

Novo Nordisk is another step closer to launching its once-weekly insulin icodec now that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended it for marketing authorization. Novo said Thursday that it expects to have full authorization in the EU within about two months. While Novo’s progression of its once-weekly insulin shot has been overshadowed by impressive weight loss data from its oral amycretin and semaglutide’s market success, an approval would make Novo the first to offer basal insulin on a weekly instead of a daily basis. Novo is also investigating icodec with its GLP-1 semaglutide.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Novo Nordisk A/S

The European Medicines Agency

Novo Klinik-Service GmbH

Indications

Targets

Drugs

Icodec InsulinAmycretinSemaglutide (Novo Nordisk)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.